as we can see that Lupin Limited is showing strong traction in the pharma space supported by robust earnings growth and improving global business outlook. The company has delivered consistent revenue expansion driven by strong U.S. sales growth and new product launches, with overall sales rising more than 25% YoY in recent quarters, reflecting solid demand and execution strengthWarning-
Disclaimer– Registration granted by SEBI, membership of a SEBI recognized supervisory body (BSE) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Disclosure– Investments in securities market are subject to market risks, read all the related documents carefully before investing.